Transaction Expected to Close in the Coming
Days
Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling
the development and supply of better treatments for patients
worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life
sciences investment firm, today announced that the companies have
fulfilled all regulatory closing conditions for their pending
transaction. The companies now expect to close the transaction in
the coming days.
“Today represents an important step in our transition to private
ownership under Novo Holdings, a leading life sciences investment
firm,” said Alessandro Maselli, President and Chief Executive
Officer of Catalent. “As we approach transaction close, I want to
thank the Catalent team for all their hard work and share my
excitement for our company’s bright future. With the support of
Novo Holdings and access to additional resources, Catalent will be
well-positioned to drive innovation and enhance offerings for the
benefit of customers and the patients they serve, ultimately
accelerating our strategy to create value for stakeholders.”
“We are pleased to have achieved this latest milestone, which we
believe reflects the significant benefits the proposed transaction
is expected to deliver,” said Jonathan Levy, Senior Partner, Novo
Holdings. “As we near close, we are enthusiastic about partnering
with and supporting the Catalent team in its mission to drive
innovation in the healthcare system and improve patient
outcomes.”
For additional information associated with the transaction,
please visit transaction.catalent.com.
Advisors Citi and J.P. Morgan served as financial
advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP
served as legal advisor to Catalent and Jones Day served as legal
advisor to the Catalent Board of Directors. Morgan Stanley &
Co. LLC served as financial advisor to Novo Holdings. Goodwin
Procter LLP and Linklaters LLP served as legal advisors to Novo
Holdings. Arnold & Porter Kaye Scholer LLP and Davis Polk &
Wardwell LLP served as legal advisors to Novo Nordisk.
About Novo Holdings A/S Novo Holdings is a holding and
investment company that is responsible for managing the assets and
the wealth of the Novo Nordisk Foundation. The purpose of Novo
Holdings is to improve people's health and the sustainability of
society and the planet by generating attractive long-term returns
on the assets of the Novo Nordisk Foundation.
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is
the controlling shareholder of Novo Nordisk A/S and Novonesis A/S
(formerly Novozymes A/S) and manages an investment portfolio with a
long-term return perspective. In addition to managing a broad
portfolio of equities, bonds, real estate, infrastructure and
private equity assets, Novo Holdings is a world-leading life
sciences investor. Through its Seed, Venture, Growth, Asia,
Planetary Health and Principal Investments teams, Novo Holdings
invests in life science companies at all stages of development. As
of year-end 2023, Novo Holdings had total assets of EUR 149
billion. www.novoholdings.dk
About Catalent, Inc. Catalent, Inc. (NYSE: CTLT), is a
global leader in enabling pharma, biotech, and consumer health
partners to optimize product development, launch, and full
life-cycle supply for patients around the world. With broad and
deep scale and expertise in development sciences, delivery
technologies, and multi-modality manufacturing, Catalent is a
preferred industry partner for personalized medicines, consumer
health brand extensions, and blockbuster drugs. Catalent helps
accelerate over 1,500 partner development programs and launch over
150 new products every year. Its flexible manufacturing platforms
at over 50 global sites supply nearly 70 billion doses of nearly
8,000 products annually. Catalent’s expert workforce of
approximately 17,000 includes more than 3,000 scientists and
technicians. Headquartered in Somerset, New Jersey, the company
generated approximately $4.4 billion in revenue in its 2024 fiscal
year. For more information, visit www.catalent.com.
Forward-Looking Statements This press release, and any
related oral statements, may include both historical and
forward-looking statements and guidance. All statements other than
statements of historical fact, are, or may be deemed to be,
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements generally can be identified by the use of statements
that include phrases such as “believe,” “expect,” “anticipate,”
“intend,” “estimate,” “plan,” “project,” “predict,” “hope,”
“foresee,” “likely,” “may,” “could,” “target,” “will,” “would,” or
other words or phrases with similar meanings. Similarly, statements
that describe Catalent’s objectives, plans, or goals are, or may
be, forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize,
actual results could vary materially from Catalent’s expectations,
projections, and guidance. Some of the factors that could cause
actual results to differ materially from forward-looking statements
include, but are not limited to, the pending merger of Catalent
with an affiliate of Novo Holdings (the “Merger”), the completion
of the Merger on anticipated terms and timing, including obtaining
antitrust and other regulatory approvals and clearances, the
satisfaction of other conditions to the completion of the Merger,
potential litigation relating to the Merger that could be
instituted by or against Catalent, Novo Holdings or their
respective affiliates, directors or officers, including the effects
of any outcomes related thereto, the risk that disruptions from the
Merger will harm Catalent’s relationships, and certain restrictions
during the pendency of the Merger that may impact Catalent’s
ability to pursue attractive business opportunities or strategic
transactions.
These forward-looking statements speak only as of the date of
this press release or as of the date they are made, and Catalent
does not undertake to and specifically disclaims any obligation to
publicly release the results of any updates or revisions to these
forward-looking statements that may be made to reflect future
events or circumstances after the date of such statements or to
reflect the occurrence of anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241213700784/en/
Catalent Investor: Paul Surdez +1 (732) 537-6325
investors@catalent.com Media: Laura Hortas +1(609) 240-7025
media@catalent.com Novo Holdings (Global inquiries)
Marie-Louise Jersin, Senior Communications Partner (US inquiries)
Dora Gonzalez, Public Relations Specialist
novoholdingsmedia@novo.dk
Catalent (NYSE:CTLT)
過去 株価チャート
から 11 2024 まで 12 2024
Catalent (NYSE:CTLT)
過去 株価チャート
から 12 2023 まで 12 2024
